CARSGEN-B (02171): Research Findings Update on In Vivo CAR-T Candidate Product CT1182

date
18:07 22/11/2026
avatar
GMT Eight
CARSGEN-B (02171) announced preliminary clinical data on CT1182 (KJ-C2529), an in vivo CAR-T candidate product targeting CD19/CD20 developed on the Company's self-developed CARvivo platform, for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data show that this in vivo CAR-T candidate product has preliminary favorable safety and encouraging efficacy signals.
CARSGEN-B (02171) announced preliminary clinical data for CT1182 (KJ-C2529), an in vivo CAR-T candidate product targeting CD19/CD20 developed on the Company's self-developed CARvivo platform, for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data show that this in vivo CAR-T candidate product has preliminary favorable safety and encouraging efficacy signals. As of October 31, 2026, the dose exploration range in the clinical trial was 1.210^8 TU to 7.210^8 TU, with enrollment of 5 patients with diffuse large B-cell lymphoma (DLBCL) and 1 patient with blastic mantle cell lymphoma (MCL). All 6 patients had aggressive lymphoma subtypes and Ann Arbor stage IV disease, with a median of 3 prior lines of therapy and a median total tumor burden (SPD) of 1,927.5 mm, including 2 patients who had previously received T-cell-specific bispecific antibody therapy. With a median follow-up of approximately 3.2 months, among the 6 efficacy-evaluable patients, 3 achieved complete response (CR) and 2 achieved partial response (PR). As of the data cutoff date, all responses were ongoing. CR was observed at the starting dose, and the longest response duration had lasted nearly 5 months. CR was also observed in 1 patient resistant to T-cell-specific bispecific antibodies, while another patient resistant to T-cell-specific bispecific antibodies showed no effective CAR-T expansion due to T-cell exhaustion and CD20 antigen loss. Among the 6 patients evaluable for dose-limiting toxicity (DLT), no treatment-related serious adverse events (SAEs), DLTs, or infusion-related reactions (IRRs) were observed; no infusion-related biphasic cytokine elevation, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or immune effector cell-associated neurotoxicity syndrome (ICANS) were seen; only grade 1 cytokine release syndrome (CRS) occurred. Hematologic toxicity was mild; apart from one case of grade 3 leukopenia that could not be fully ruled out as disease-related, no other treatment-related grade 3 hematologic toxicities occurred. The early clinical data demonstrate the safety and effective gene delivery of the CARvivo technology platform. In the disclosed data, encouraging early efficacy was achieved even in low-dose and relatively high-risk patients. The safety profile was excellent, with no virus infusion-related biphasic cytokine elevation, no IRRs observed, and mild hematologic and hepatic toxicity. Its safety profile supports development in the outpatient treatment setting. Complete B-cell depletion was observed in all responding patients, suggesting potential use in other B-cell diseases such as autoimmune diseases. The Company plans to further explore a broader dose range in subsequent trials to explore a possible recommended Phase II dose (RP2D) and optimize the dose-response relationship. The Company expects to submit a registration clinical trial application in the first half of 2027.